JP2008501339A - Ａａｖベクターの凝集を防ぐための組成物およびその方法 - Google Patents

Ａａｖベクターの凝集を防ぐための組成物およびその方法 Download PDF

Info

Publication number
JP2008501339A
JP2008501339A JP2007515525A JP2007515525A JP2008501339A JP 2008501339 A JP2008501339 A JP 2008501339A JP 2007515525 A JP2007515525 A JP 2007515525A JP 2007515525 A JP2007515525 A JP 2007515525A JP 2008501339 A JP2008501339 A JP 2008501339A
Authority
JP
Japan
Prior art keywords
aggregation
vector
virion
ionic strength
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007515525A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン・フレイザー・ライト
ク・グアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008501339(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2008501339A publication Critical patent/JP2008501339A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
JP2007515525A 2004-06-01 2005-06-01 Ａａｖベクターの凝集を防ぐための組成物およびその方法 Pending JP2008501339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57599704P 2004-06-01 2004-06-01
US63922204P 2004-12-22 2004-12-22
PCT/US2005/019235 WO2005118792A1 (en) 2004-06-01 2005-06-01 Compositions and methods to prevent aav vector aggregation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012040561A Division JP5769650B2 (ja) 2004-06-01 2012-02-27 Ａａｖベクターの凝集を防ぐための組成物およびその方法

Publications (1)

Publication Number Publication Date
JP2008501339A true JP2008501339A (ja) 2008-01-24

Family

ID=35462907

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2007515525A Pending JP2008501339A (ja) 2004-06-01 2005-06-01 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2012040561A Expired - Lifetime JP5769650B2 (ja) 2004-06-01 2012-02-27 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2014014070A Pending JP2014111625A (ja) 2004-06-01 2014-01-29 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2016058761A Pending JP2016195587A (ja) 2004-06-01 2016-03-23 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2018218970A Pending JP2019058177A (ja) 2004-06-01 2018-11-22 Ａａｖベクターの凝集を防ぐための組成物およびその方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2012040561A Expired - Lifetime JP5769650B2 (ja) 2004-06-01 2012-02-27 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2014014070A Pending JP2014111625A (ja) 2004-06-01 2014-01-29 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2016058761A Pending JP2016195587A (ja) 2004-06-01 2016-03-23 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2018218970A Pending JP2019058177A (ja) 2004-06-01 2018-11-22 Ａａｖベクターの凝集を防ぐための組成物およびその方法

Country Status (10)

Country Link
US (4) US7704721B2 (Direct)
EP (3) EP4170024A1 (Direct)
JP (5) JP2008501339A (Direct)
BR (1) BRPI0511764B8 (Direct)
CA (1) CA2569244C (Direct)
DK (2) DK1751275T3 (Direct)
ES (2) ES2932278T3 (Direct)
HU (2) HUE035418T2 (Direct)
MX (3) MX360727B (Direct)
WO (1) WO2005118792A1 (Direct)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524101A (ja) * 2016-07-21 2019-09-05 スパーク セラピューティクス インコーポレイテッドＳｐａｒｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高収率の組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクターを生成するための、規模拡大可能な高回収率の方法、及びそれにより生成される組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクター
JP2021505610A (ja) * 2017-12-05 2021-02-18 アプライド ジェネティック テクノロジーズ コーポレイション ウイルス粒子のための製剤最適化
JP2021533757A (ja) * 2018-08-10 2021-12-09 リジェネクスバイオ インコーポレイテッド 組換えａａｖ生成のためのスケーラブルな方法
JP2023113623A (ja) * 2019-04-19 2023-08-16 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
JP2023536883A (ja) * 2020-08-07 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド 高度に精製されたウイルス粒子のための製剤

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090047255A1 (en) * 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
US8067241B2 (en) * 2009-08-26 2011-11-29 General Electric Company Method and apparatus for antigen retrieval process
JP2013517798A (ja) * 2010-01-28 2013-05-20 ザ チルドレンズ ホスピタル オブ フィラデルフィア ウイルスベクター精製における拡張可能な製造プラットフォームおよび遺伝子治療における使用のための高純度ウイルスベクター
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
EP2686423A4 (en) * 2011-03-14 2015-01-28 Nat Res Council Canada METHOD FOR PRODUCING VIRUSES IN CELLS
AU2012340567B2 (en) 2011-11-22 2017-11-23 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
WO2013090409A1 (en) 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
DK3010537T3 (en) * 2013-06-17 2018-09-24 De Staat Der Nederlanden Vert Door De Mini Van Vws Mini Van Volksgezondheit Welzijn En Sport PROCEDURE FOR PREVENTING AGGREGATION OF VIRUS COMPONENTS
US10161011B2 (en) 2013-11-29 2018-12-25 Takara Bio Inc. Method for quantifying adeno-associated virus
US10471132B2 (en) 2014-04-25 2019-11-12 Genethon Treatment of hyperbilirubinemia
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
WO2016004319A1 (en) * 2014-07-02 2016-01-07 University Of Florida Research Foundation, Inc. Compositions and methods for purifying recombinant adeno-associated virus
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
CN107207556B (zh) 2014-11-14 2020-12-08 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CN107428799A (zh) 2015-01-13 2017-12-01 阿尔法韦士曼公司 纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
IL259441B2 (en) 2015-11-16 2024-01-01 Res Inst Nationwide Childrens Hospital Materials and methods for treatment of titin-based myopathies and other titinopaties
EP4215605A1 (en) * 2015-12-11 2023-07-26 The Trustees of The University of Pennsylvania Scalable purification method for aav8
FI3436593T3 (fi) 2016-03-28 2023-03-16 Ultragenyx Pharmaceutical Inc Adenoviruksen lämpöinaktivointimenetelmiä
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102652994B1 (ko) 2016-05-18 2024-04-01 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
WO2018039375A1 (en) 2016-08-23 2018-03-01 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
KR20240001721A (ko) 2016-09-12 2024-01-03 제네똥 산-알파 글루코시다제 변이체 및 이의 용도
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
JP7051132B2 (ja) 2016-09-16 2022-04-11 ロイコケア・アクチェンゲゼルシャフト ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
AU2017391165B2 (en) * 2016-11-04 2023-02-02 Takeda Pharmaceutical Company Limited Adeno-associated virus formulations
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US10294452B2 (en) * 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
US11357735B2 (en) 2017-02-01 2022-06-14 Centre National De La Recherche Scientifique Particles and compositions comprising the same for transfection
CN110914419A (zh) 2017-03-10 2020-03-24 吉尼松公司 糖原贮积病iii的治疗
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
AU2018302016A1 (en) 2017-07-17 2020-02-06 The Regents Of The University Of California Trajectory array guide system
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2019067840A1 (en) 2017-09-29 2019-04-04 Voyager Therapeutics, Inc. RESTRICTING CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE FROM FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
CA3077426A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111566220A (zh) * 2017-11-08 2020-08-21 阿维克斯公司 制备病毒载体的手段和方法及其用途
CN119770682A (zh) 2018-01-31 2025-04-08 国家儿童医院研究所 2c型肢带型肌营养不良的基因疗法
WO2019154939A1 (en) 2018-02-07 2019-08-15 Genethon Hybrid regulatory elements
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
EP3784780A1 (en) 2018-04-27 2021-03-03 Voyager Therapeutics, Inc. Methods for measuring the potency of aadc viral vectors
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
JP7478675B2 (ja) 2018-06-08 2024-05-07 ノバルティス アーゲー 薬物製品の効力を測定するための細胞ベースアッセイ
EP3814492A4 (en) 2018-06-29 2022-02-23 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
MX2020014119A (es) 2018-06-29 2021-06-18 Res Inst Nationwide Childrens Hospital Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a.
EP3818161A1 (en) 2018-07-02 2021-05-12 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CN112469427A (zh) * 2018-07-11 2021-03-09 百特奥尔塔公司 Aav组合物
MX2021000810A (es) 2018-07-24 2021-04-28 Voyager Therapeutics Inc Sistemas y metodos para producir formulaciones de terapia genetica.
EP4230733A1 (en) 2018-08-08 2023-08-23 Genethon Mini-gde for the treatment of glycogen storage disease iii
JP7403852B2 (ja) 2018-08-20 2023-12-25 ウーハン ニューロフス バイオテクノロジー リミテッド カンパニー レーベル遺伝性視神経症を治療するための組成物及び方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
TW202039858A (zh) 2019-01-18 2020-11-01 美商航海家醫療公司 用於生產aav顆粒之方法及系統
SG11202109113TA (en) 2019-02-26 2021-09-29 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
EP3952920A1 (en) 2019-04-08 2022-02-16 Genethon Hybrid promoters for muscle expression
EP3956354A1 (en) 2019-04-19 2022-02-23 Genethon Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
CA3147574A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021028559A1 (en) 2019-08-14 2021-02-18 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
US11155835B2 (en) 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
US11401530B2 (en) 2019-08-19 2022-08-02 The Catholic University Of America Bacteriophage-based artificial viruses for human genome remodeling
SI4017871T1 (sl) 2019-08-21 2024-06-28 Research Institute At Nationwide Children's Hospital Dostava alfa-sarkoglikana z adeno povezanim virusnim vektorjem in zdravljenje mišične distrofije
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CA3156984A1 (en) 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
CN114555808A (zh) 2019-10-22 2022-05-27 吉尼松公司 嵌合多肽及其用途
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
BR112022016596A2 (pt) 2020-02-21 2022-11-16 Akouos Inc Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
EP4157301A4 (en) * 2020-06-02 2025-03-19 Janssen Biotech, Inc. Materials and methods for viral purification
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4200410A1 (en) 2020-08-24 2023-06-28 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
EP4237545A1 (en) 2020-11-02 2023-09-06 BioMarin Pharmaceutical Inc. Process for enriching adeno-associated virus
WO2022122883A1 (en) 2020-12-09 2022-06-16 Genethon Lysosomal acid lipase variants and uses thereof
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
AU2022271280A1 (en) * 2021-05-07 2023-11-09 Board Of Regents, The University Of Texas System Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
CN117897492A (zh) 2021-08-04 2024-04-16 吉尼松公司 用于肌肉和cns中的基因表达的杂合启动子
JP2024534410A (ja) 2021-09-16 2024-09-20 ノバルティス アーゲー 新規転写因子
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
WO2023073526A1 (en) 2021-10-25 2023-05-04 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
WO2023175584A1 (en) 2022-03-17 2023-09-21 Innoskel Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
WO2023175585A1 (en) 2022-03-17 2023-09-21 Innoskel Hybrid promoters and their use in osteolysis syndrome
CA3255627A1 (en) 2022-05-06 2023-11-09 Novartis Ag NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
JP2025524363A (ja) 2022-06-09 2025-07-30 ジェネトン 糖原病ｉｉｉの処置のためのｎ末端短縮型ｇｄｅ
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202426017A (zh) * 2022-11-24 2024-07-01 俄羅斯聯邦商拜奧卡德聯合股份公司 非包膜病毒的藥物組合物
CN121420060A (zh) 2023-06-29 2026-01-27 吉尼松公司 用于治疗糖原贮积病iii的n-端截短的糖原脱支酶
EP4606892A1 (en) 2024-02-23 2025-08-27 Merck Patent GmbH Methods for the production of viral particles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ATE348155T1 (de) * 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2399321C (en) * 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
DE60313451T2 (de) * 2002-05-14 2008-01-03 Merck & Co., Inc. Verfahren zur reinigung von adenovirus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524101A (ja) * 2016-07-21 2019-09-05 スパーク セラピューティクス インコーポレイテッドＳｐａｒｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高収率の組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクターを生成するための、規模拡大可能な高回収率の方法、及びそれにより生成される組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクター
JP7153009B2 (ja) 2016-07-21 2022-10-13 スパーク セラピューティクス インコーポレイテッド 高収率の組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクターを生成するための、規模拡大可能な高回収率の方法、及びそれにより生成される組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクター
JP2021505610A (ja) * 2017-12-05 2021-02-18 アプライド ジェネティック テクノロジーズ コーポレイション ウイルス粒子のための製剤最適化
JP2021533757A (ja) * 2018-08-10 2021-12-09 リジェネクスバイオ インコーポレイテッド 組換えａａｖ生成のためのスケーラブルな方法
JP2023113623A (ja) * 2019-04-19 2023-08-16 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
JP7669414B2 (ja) 2019-04-19 2025-04-28 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
JP2023536883A (ja) * 2020-08-07 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド 高度に精製されたウイルス粒子のための製剤

Also Published As

Publication number Publication date
US20160083694A1 (en) 2016-03-24
EP1751275A1 (en) 2007-02-14
EP1751275B1 (en) 2017-08-16
JP5769650B2 (ja) 2015-08-26
MX2019006353A (es) 2022-06-27
ES2647477T3 (es) 2017-12-21
EP3290513A1 (en) 2018-03-07
US7704721B2 (en) 2010-04-27
WO2005118792A1 (en) 2005-12-15
EP1751275A4 (en) 2008-01-23
CA2569244C (en) 2017-02-14
HUE060433T2 (hu) 2023-03-28
US20110076744A1 (en) 2011-03-31
EP4170024A1 (en) 2023-04-26
DK1751275T3 (da) 2017-11-27
HUE035418T2 (en) 2018-05-02
DK3290513T3 (da) 2022-12-12
MXPA06014030A (es) 2007-10-08
JP2012143233A (ja) 2012-08-02
US20060035364A1 (en) 2006-02-16
US20170247664A1 (en) 2017-08-31
MX360727B (es) 2018-11-14
CA2569244A1 (en) 2005-12-15
BRPI0511764A (pt) 2008-01-08
US9051542B2 (en) 2015-06-09
JP2014111625A (ja) 2014-06-19
JP2019058177A (ja) 2019-04-18
BRPI0511764B8 (pt) 2021-05-25
EP3290513B1 (en) 2022-09-07
JP2016195587A (ja) 2016-11-24
BRPI0511764B1 (pt) 2017-10-24
ES2932278T3 (es) 2023-01-17

Similar Documents

Publication Publication Date Title
JP5769650B2 (ja) Ａａｖベクターの凝集を防ぐための組成物およびその方法
Huang et al. AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications
US20220072073A1 (en) Methods of heat inactivation of adenovirus
Yan et al. Distinct transduction difference between adeno-associated virus type 1 and type 6 vectors in human polarized airway epithelia
US10294452B2 (en) Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
Lagor et al. Adeno-associated viruses as liver-directed gene delivery vehicles: focus on lipoprotein metabolism
CN108085301A (zh) 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
KR102205026B1 (ko) 시험관내에서 생성된 바이러스의 정제 방법 및 그 바이러스에 대한 제거 분석 방법
CN101018858A (zh) 防止aav载体聚集的组合物和方法
HK40091911A (en) Compositions and methods to prevent aav vector aggregation
JP7591579B2 (ja) 核磁気共鳴緩和測定によってａａｖ粒子のローディング状態を決定するための方法
Tamura et al. Production of Adeno-Associated Virus Vector Serotype rh. 10 and Optimization of Its Purification via Chloroform Extraction
US20230374468A1 (en) Formulations for viral vectors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110523

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120